mesoblast


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

mesoblast

[′me·zō‚blast]
(embryology)
Undifferentiated mesoderm of the middle layer of the embryo.
References in periodicals archive ?
Mesoblast Limited is a developer of biologic products for the broad field of regenerative medicine.
The flexibility of Rave allows Mesoblast to proactively adjust a trial s data validation plan and management processes, and also apply learnings to other studies in a timely fashion to improve trial quality and efficiency.
Results generated from this Phase 2 trial may enable Mesoblast to expand its Type 2 diabetes and metabolism therapeutic programs to address the large unmet medical needs of Type 2 diabetes patients with renal complications and the associated increase in cardiovascular morbidity and mortality.
The benefits derived from acquiring the approved and late-phase MSC products include: *near term launch of a mesenchymal lineage product in major jurisdictions; *broadened late -phase clinical programs in strategic areas of focus; and *leveraged roll out of infrastructure, skills and expertise needed to commercialize Mesenchymal Precursor Cell (MPC) products Mesoblast said.
Professor Itescu said that the key to Mesoblast having emerged as the world's leading regenerative medicine company lies in the ability of its leadership team to understand and manage corporate risk and to build upon a substantial foundation of knowledge.
Mesoblast will pay Osiris US$20 million upon closing of the transaction, with US$15 million in Mesoblast stock payable upon transfer of the assigned assets.
I am proud to report the progress we've made over the past year at Mesoblast.
The flexibility of Rave allows Mesoblast to proactively adjust a trial's data validation plan and management processes, and also apply learnings to other studies in a timely fashion to improve trial quality and efficiency.
3, 1 and 2 million MPC/kg, identical to the doses Mesoblast has already shown to cause a dose-dependent reduction in blood glucose levels over an 8-week period in 17 non-human primates with hyperglycemia, obesity and Type 2 Diabetes.
Mesoblast, Ltd, Melbourne, Australia, announced it been approved by the US Food and Drug Administration (FDA) to begin a Phase 3 clinical trial for bone marrow regeneration in patients with blood cancers.
Key Regions - Americas - APAC - EMEA Key Vendors - Caladrius Biosciences - Celgene - Mesoblast - Pluristem Therapeutics Other Prominent Vendors - Athersys - CHA Bio & Diostech - Cytori Therapeutics - Nuo Therapeutics - Ocata Therapeutics - Opexa Therapeutics - Osiris Therapeutics - Teva Pharmaceuticals - United Therapeutics KeyMarket Driver - Effective Treatment of Life-threatening Diseases - For a full, detailed list, view our report Key Market Challenge - Stringent Regulations - For a full, detailed list, view our report Key Market Trend - Growing Public Awareness - For a full, detailed list, view our report Key Questions Answered in this Report - What will the market size be in 2019 and what will the growth rate be?